About
Replimune Group, Inc. develops oncolytic immunotherapies designed to activate systemic anti-tumor immune responses for the treatment of various cancers, including its FDA-approved therapy TUDRIQEV for advanced melanoma.
Explore Replimune Group, Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.